Nicklas Oscarsson

Dr. Nicklas Oscarsson


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
NONicklas Oscarsson
Nicklas Oscarsson
BMBernd Müller
Bernd Müller
ARAnders Rosén
Anders Rosén
PLPär Lodding
Pär Lodding
JMJohan Mölne
Johan Mölne
HSHelén Seeman-Lodding
Helén Seeman-Lodding

1 November 2013 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
NONicklas Oscarsson
Nicklas Oscarsson
PAPer Arnell
Per Arnell
PLPär Lodding
Pär Lodding
SRSven-Erik Ricksten
Sven-Erik Ricksten
HSHeléne Seeman-Lodding
Heléne Seeman-Lodding

1 February 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
NONicklas Oscarsson
Nicklas Oscarsson
LNL. Ny
L. Ny
JMJ. Mölne
J. Mölne
FLF. Lind
F. Lind
SRS.-E. Ricksten
S.-E. Ricksten
DGD. Giglio
D. Giglio

5 July 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
Anders KjellbergAnders Kjellberg
Anders Kjellberg
JDJohan Douglas
Johan Douglas
MPMichael T Pawlik
Michael T Pawlik
MKMichael Kraus
Michael Kraus
NONicklas Oscarsson
Nicklas Oscarsson
PLPeter Lindholm
Peter Lindholm
Introduction COVID-19 may cause severe pneumonitis and trigger a massive inflammatory response that requires ventilatory support. The intensive care unit (ICU)-mortality has been reported to be as high as 62%. Dexamethasone is the only of all anti-inflammatory drugs that have been tested to date that has shown a positive effect on mortality. We aim to explore if treatment with hyperbaric oxygen (HBO) is safe and effective for patients with severe COVID-19. Our hypothesis is that HBO can prevent ICU admission, morbidity and mortality by attenuating the inflammatory response. The primary objective is to evaluate if HBO reduces the number of ICU admissions compared with best practice treatment for COVID-19, main secondary objectives are to evaluate if HBO reduces the load on ICU resources, morbidity and mortality and to evaluate if HBO mitigates the inflammatory reaction in COVID-19. Methods and analysis A randomised, controlled, phase II, open label, multicentre trial. 200 subjects with severe COVID-19 and at least two risk factors for mortality will be included. Baseline clinical data and blood samples will be collected before randomisation and repeated daily for 7 days, at days 14 and 30. Subjects will be randomised with a computer-based system to HBO, maximum five times during the first 7 days plus best practice treatment or only best practice treatment. The primary endpoint, ICU admission, is defined by criteria for selection for ICU. We will evaluate if HBO mitigates the inflammatory reaction in COVID-19 using molecular analyses. All parameters are recorded in an electronic case report form. An independent Data Safety Monitoring Board will review the safety parameters. Ethics and dissemination The trial is approved by The National Institutional Review Board in Sweden (2020-01705) and the Swedish Medical Product Agency (5.1-2020-36673). Positive, negative and any inconclusive results will be published in peer-reviewed scientific journals with open access. Trial registration NCT04327505. EudraCT number: 2020-001349-37.

19 April 2025 in eClinicalMedicine
Verified
Journal Article
Open access
NONicklas Oscarsson
Nicklas Oscarsson
ARAnders Rosén
Anders Rosén
BMBernd Müller
Bernd Müller
LKLotta Renström Koskela
Lotta Renström Koskela
DGDaniel Giglio
Daniel Giglio
HSHelén Seeman-Lodding
Helén Seeman-Lodding

10 February 2022 in European Journal of Applied Physiology
Verified
Journal Article
Open access
PDF file
ARAnders Rosén
Anders Rosén
MGMikael Gennser
Mikael Gennser
NONicklas Oscarsson
Nicklas Oscarsson
AKAndreas Kvarnström
Andreas Kvarnström
GSGöran Sandström
Göran Sandström
HZHenrik Zetterberg
Henrik Zetterberg
Purpose: It is speculated that diving might be harmful to the nervous system. The aim of this study was to determine if established markers of neuronal injury were increased in the blood after diving. Methods: Thirty-two divers performed two identical dives, 48 h apart, in a water-filled hyperbaric chamber pressurized to an equivalent of 42 m of sea water for 10 min. After one of the two dives, normobaric oxygen was breathed for 30 min, with air breathed after the other. Blood samples were obtained before and at 30–45 and 120 min after diving. Concentrations of glial fibrillary acidic, neurofilament light, and tau proteins were measured using single molecule array technology. Doppler ultrasound was used to detect venous gas emboli. Results: Tau was significantly increased at 30–45 min after the second dive (p < 0.0098) and at 120 min after both dives (p < 0.0008/p < 0.0041). Comparison of matching samples showed that oxygen breathing after diving did not influence tau results. There was no correlation between tau concentrations and the presence of venous gas emboli. Glial fibrillary acidic protein was decreased 30–45 min after the first dive but at no other point. Neurofilament light concentrations did not change. Conclusions: Tau seems to be a promising marker of dive-related neuronal stress, which is independent of the presence of venous gas emboli. Future studies could validate these results and determine if there is a quantitative relationship between dive exposure and change in tau blood concentration.